Stoke Therapeutics (STOK) Capital Expenditures Growth (1y) (2019 - 2026)
Stoke Therapeutics (STOK) Capital Expenditures Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 143.40% |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | 1,207.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,207.41% |
| Dec 31, 2025 | 201.04% |
| Sep 30, 2025 | 187.23% |
| Jun 30, 2025 | -53.85% |
| Mar 31, 2025 | 350.00% |
| Dec 31, 2024 | -16.16% |
| Sep 30, 2024 | -112.27% |
| Jun 30, 2024 | -93.80% |
| Mar 31, 2024 | -96.36% |
| Dec 31, 2023 | 180.35% |
| Sep 30, 2023 | 210.06% |
| Jun 30, 2023 | 1,064.37% |
| Mar 31, 2023 | -80.38% |
| Dec 31, 2022 | -205.56% |
| Sep 30, 2022 | -227.47% |
| Jun 30, 2022 | -116.73% |
| Mar 31, 2022 | 312.25% |
| Dec 31, 2021 | 485.71% |
| Sep 30, 2021 | 658.33% |
| Jun 30, 2021 | 10,300.00% |